SCHEMBL3662266

SCHEMBL3662266

OCCN1CCN(c2ncc(Br)cn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP3A4 P08684 1/20 0.53
HDAC6 Q9UBN7 1/20 0.49
HTT P42858 1/20 0.47
CYP2D6 P10635 1/20 0.45
DUSP3 P51452 1/20 0.45
PTPN5 P54829 1/20 0.45
PTPN11 Q06124 1/20 0.45
HTR2A P28223 1/20 0.44
DRD3 P35462 1/20 0.44
ACHE P22303 2/20 0.42
SIGMAR1 Q99720 4/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
GAA P10253 1/20 0.42
DRD2 P14416 1/20 0.42
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19145298 0.83 MEN1 (0.53) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL6399783 0.80 MEN1 (0.58) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL21780751 0.80 CYP2C9 (0.50) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL15383624 0.79 SIGMAR1 (0.48) CYP2D6SIGMAR1
SCHEMBL19105533 0.79 CYP2C9 (0.49) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL23870214 0.79 KMT2A (0.49) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL5257923 0.79 GAA (0.55) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL22450312 0.79 HDAC6 (0.52) MEN1KMT2ACYP2C9HDAC6ACHE
SCHEMBL12412689 0.79 CYP2C9 (0.49) MEN1KMT2ACYP2C19CYP2C9CYP3A4
SCHEMBL28116123 0.78 PANK3 (0.41) HDAC6HTTKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed
US-8299065-B2 Antibacterial condensed thiazoles BIOTA EUROPE LTD. (GB) 2012-10-30 US disclosed
US-8299065-B2 Antibacterial condensed thiazoles BIOTA EUROPE LTD. (GB) 2012-10-30 US disclosed
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2010-12-02 US disclosed
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2010-12-02 US disclosed
EP-2231653-A1 ANTIBACTERIAL CONDENSED THIAZOLES Biota Europe Ltd (GB) 2010-09-29 EP disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAPK7, MAPK14 MEN1 4324/4885KMT2A 2228/4885CYP2C19 2763/4885
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES NEK6, NEK1, TXK MEN1 2077/4885KMT2A 3154/4885CYP2C19 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.